Tirzepatide vs Semaglutide: Which GLP-1 Is Better for Weight Loss?
Medication evidence and practical access information. We have no verified affiliate offer for this exact medication; the guide below is informational, not a provider availability claim.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
No verified affiliate offer for this medication
This means we have not verified a supplied affiliate link to a page offering this exact medication—not that the medication is unavailable everywhere. We do not substitute another treatment or a general provider homepage.
Tirzepatide and semaglutide are the two dominant GLP-1 receptor agonists for weight management. The SURMOUNT-1 trial (NEJM 2022) showed 20.9% mean weight loss with tirzepatide 15 mg at 72 weeks, while the STEP 1 trial (NEJM 2021) showed 14.9% with semaglutide 2.4 mg at 68 weeks. This page compares the clinical evidence, side-effect profiles, pricing, and availability of both medications across telehealth providers.
Semaglutide is a GLP-1 receptor agonist (Wegovy for weight loss, Ozempic for diabetes). Tirzepatide is a dual GLP-1/GIP receptor agonist (Zepbound for weight loss, Mounjaro for diabetes). Both are weekly subcutaneous injections. Tirzepatide's dual-receptor mechanism produces greater weight loss in clinical trials but may also cause more GI side effects during titration. Both are available as FDA-approved brand-name products and as compounded formulations from telehealth providers.
This comparison is for patients deciding between tirzepatide and semaglutide — whether brand-name or compounded. Patients who prioritize maximum weight loss and can tolerate GI side effects may prefer tirzepatide. Patients who want the longest safety track record, cardiovascular benefit data (SELECT trial), or lower cost may prefer semaglutide. Insurance coverage often dictates the choice: many plans cover one but not the other.
Both medications are injected once weekly. Titration takes 16–20 weeks to reach maintenance dose. Common side effects include nausea (40–50%), diarrhea (25–30%), and constipation (20–25%). Tirzepatide users report slightly higher rates of GI events during titration but similar tolerability at maintenance. Weight loss typically becomes visible at 8–12 weeks and plateaus at 9–12 months.
Verified Offers for tirzepatide
Frequently Asked Questions
Which produces more weight loss — tirzepatide or semaglutide?
In clinical trials, tirzepatide (20.9% at 72 weeks in SURMOUNT-1) produced more weight loss than semaglutide (14.9% at 68 weeks in STEP 1). However, these are different trials with different populations; no head-to-head RCT has been published.
Is tirzepatide safer than semaglutide?
Both have similar safety profiles. Semaglutide has longer post-market surveillance data and the SELECT cardiovascular outcomes trial showing 20% MACE reduction. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing.
Which is cheaper — compounded tirzepatide or compounded semaglutide?
Compounded semaglutide is typically $59–$149/mo while compounded tirzepatide is $99–$299/mo. Semaglutide is generally 30–50% cheaper at equivalent providers.
Can I switch from semaglutide to tirzepatide?
Yes, many telehealth providers support switching. The typical protocol is to start tirzepatide at 2.5 mg regardless of your semaglutide dose, then titrate up. Discuss timing with your prescriber.